Melatonina, potencjalnie nowy lek przeciwnowotworowy u zwierząt

• Autorzy: Zan R. , Rolinski Z. , Kowalski C. , Burmanczuk A.

Warianty tytułu

EN

Melatonin, a potential new anticancer drug in animals

• Języki publikacji: PL

Abstrakty

EN

The article describes the possibility of using melatonin in cases of neoplastic diseases in animals. Most observational studies show an association between melatonin and cancer in animals and humans. The mechanisms by which melatonin may act in this way have not been fully elucidated. The oncostatic action of melatonin in mammary cancer, as well as in uterine and prostate cancer, may result from the modulating effect on the enzymes involved in the local synthesis of estrogens. Many biological effects of melatonin, including antitumor activity, are caused by the activation of membrane receptors (MT1 and MT2), connected with regulatory proteins (G proteins). Other possible anti-cancer mechanisms include anti-angiogenic activity, anti-inflammatory activity, protection from oxidative damage, and immunostimulation. Many studies confirm the efficacy and safety of melatonin in cancer treatment. Melatonin can be used with chemotherapy in animals not only to support the action of anticancer drugs, but also to reduce their toxicity.

Słowa kluczowe

PL

psy; koty; melatonina; leki weterynaryjne; leki przeciwnowotworowe; nowotwory; choroby zwierzat; leczenie; mechanizm dzialania; dzialanie przeciwnowotworowe; terapia przeciwnowotworowa; bezpieczenstwo stosowania lekow; nowe leki; weterynaria

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2012
• Tom: 68
• Numer: 06
• Opis fizyczny: s.343-348,rys.,bibliogr.

Twórcy

autor

Zan R.

• Zakład Farmakologii, Katedra Przedklinicznych Nauk Weterynaryjnych, Wydział Medycyny Weterynaryjnej, Uniwersytet Przyrodniczy w Lublinie, u.Akademicka12, 20-033 Lublin

autor

Rolinski Z.

autor

Kowalski C.

autor

Burmanczuk A.

Bibliografia

• 1.Arendt J.: Melatonin. Clin. Endocrinol. (Oxf) 1988, 29, 205-229.
• 2.Aubert C. H., Janiaud P., Lecalvez J.: Effect of pinealectomy and melatonin on mammary tumor growth in Sprague-Dawley rats under different conditions of lighting. J. Neural. Transm. 1980, 47, 121-130.
• 3.Bailey D. B., Rassnick K. M., Erb H. N., Dykes N. L., Hoopes P. J., Page R. L.: Effect of glomerular filtration rate on clearance and myelotoxicity of carboplatin in cats with tumors. Am. J. Vet. Res. 2004, 65, 1502-1507.
• 4.Balicki I., Śmiech A., Komsta R., Brodzki A., Łopuszyński W.: Nowotwory żołądka psów w świetle badań klinicznych, histologicznych i immunohistochemicznych. Med. Weter. 2004, 60, 602-606.
• 5.Bangha E., Elsner P., Kistler G. S.: Suppression of UV-induced erythema by topical treatment with melatonin (N-acetyl-5-methoxytryptamine). A dose response study. Arch. Dermatol. Res. 1996, 288, 522-526.
• 6.Barchas J., DaCosta F., Spector S.: Acute pharmacology of melatonin. Nature 1967, 214, 919-920.
• 7.Blask D. E., Sauer L. A., Dauchy R. T.: Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr. Top. Med. Chem. 2002, 2, 113-132.
• 8.Brønden L. B., Nielsen S. S., Toft N., Kristensen A. T.: Data from the Danish veterinary cancer registry on the occurrence and distribution of neoplasms in dogs in Denmark. Vet. Rec. 2010 166, 586-590.
• 9.Carlberg C.: Gene regulation by melatonin. Ann. NY Acad. Sci. 2000, 917, 387-396.
• 10.Clanstrat B., Brun J., Chazot G.: The basic physiology and pathophysiology of melatonin. Sleep. Med. Rev. 2005, 9, 11-24.
• 11.Cohen M., Lippman M., Chabner B.: Role of pineal gland in etiology and treatment of breast cancer. Lancet 1978, 2, 814-816.
• 12.Collins R., Trowman R., Norman G., Light K., Birtle A., Fenwick E., Palmer S., Riemsma R.: A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer. Br. J. Cancer. 95, 457-462.
• 13.Cooley D. M., Waters D. J.: Skeletal neoplasms of small dogs: a retrospective study and literature review. J. Am. Anim. Hosp. Assoc. 1997, 33, 11-23.
• 14.Danielczyk K., Dziegiel P.: MT1 melatonin receptors and their role in the oncostatic action of melatonin. Postepy Hig. Med. Dośw. (Online) 2009, 63, 425-434.
• 15.Davis S., Mirick D. K., Stevens R. G.: Night shift work, light at night, and risk of breast cancer. J. Natl. Cancer Inst. 2001, 93, 1557-1562.
• 16.Dayananda T. S., Rao S., Byregowda S. M., Satyanarayana M. L., Jayachandra K. C., Shilpa V. T.: Prevalence of skin and subcutaneous tissue neoplasms in dogs. Indian Vet. J. 2009, 86, 671-673.
• 17.Dianzani M. U.: Lipid peroxidation and cancer. Crit. Rev. Oncol. Hematol. 1993, 15, 125-147.
• 18.Dreher D., Junod A. F.: Role of oxygen free radicals in cancer development. Eur. J. Cancer. 1996, 32A, 30-38.
• 19.Dubocovich M. L., Masana M. I., Benloucif S.: Molecular pharmacology and function of melatonin receptor subtypes. Adv. Exp. Med. Biol. 1999, 460, 181-190.
• 20.Fischer T. W., Slominski A., Zmijewski M. A., Reiter R. J., Paus R.: Melatonin as a major skin protectant: from free radical scavenging to DNA damage repair. Exp. Dermatol. 2008, 17, 713-730.
• 21.Fischer T. W., Zmijewski M. A., Zbytek B., Sweatman T. W., Slominski R. M., Wortsman J., Slominski A.: Oncostatic effects of the indole melatonin and expression of its cytosolic and nuclear receptors in cultured human melanoma cell lines. Int. J. Oncol. 2006, 29, 665-672.
• 22.Gonzalez A., Cos S., Martinez-Campa C., Alonso-Gonzalez C., Sanchez-Mateos S., Mediavilla M. D., Sanchez-Barcelo E. J.: Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells. J. Pineal Res. 2008, 45, 86-92.
• 23.Gonzalez R., Sanchez A., Ferguson J. A., Balmer C., Daniel C., Cohn A., Robinson W. A.: Melatonin therapy of advanced human malignant melanoma. Melanoma Res. 1991, 1, 237-243.
• 24.Guerrero J. M., Reiter R. J.: Melatonin-immune system relationships. Curr. Top. Med. Chem. 2002, 2, 167-179.
• 25.Hahn K. A., McEntee M. F., Daniel G. B., Legendre A. M., Nolan M. L.: Hematologic and systemic toxicoses associated with carboplatin administration in cats. Am. J. Vet. Res. 1997, 58, 677-679.
• 26.Hammer A., Getzy D., Ogilvie G., Upton M., Klausner J., Kisseberth W. C.: Salivary gland neoplasia in the dog and cat: survival times and prognostic factors. J. Am. Anim. Hosp. Assoc. 2001, 37, 478-482.
• 27.Hardeland R., Fuhrberg B.: Ubiquitous melatonin-Presence and effects in unicells, plants and animals. Trends. Comp. Biochem. Physiol. 1996, 2, 25-45.
• 28.Herring E. S., Smith M. M., Robertson J. L.: Lymph node staging of oral and maxillofacial neoplasms in 31 dogs and cats. J. of Vet. Dent. 2002, 19, 122-126.
• 29.Huggins C., Grand L. C., Brillantes F. P.: Mammary cancer induced by a single feeding of polynuclear hydrocarbons, and its suppression. Nature 1961, 189, 204-207.
• 30.Ibraheem M., Galbraith H., Scaife J., Ewen S.: Growth of secondary hair follicles of the Cashmere goat in vitro and their response to prolactin and melatonin. J. Anat. 1994, 185 135-142.
• 31.Jordan V. C., Murphy C. S.: Endocrine pharmacology of antiestrogens as antitumor agents. Endocr. Rev. 1990, 11, 578-610.
• 32.Jung B., Ahmad N.: Melatonin in cancer management: progress and promise. Cancer Res. 2006, 66, 9789-9793.
• 33.Karayannopoulou M., Koutinas A. F., Polizopoulou Z. S., Roubies N., Fytianou A., Saridomichelakis M. N., Kaldrymidou E.: Total serum alkaline phosphatase activity in dogs with mammary neoplasms: a prospective study on 79 natural cases. J. Vet. Med. A Physiol. Pathol. Clin. Med. 2003, 50, 501-505.
• 34.Knapp D. W., Richardson R. C., Chan T. C., Bottoms G. D., Widmer W. R., DeNicola D. B., Teclaw R., Bonney P. L., Kuczek T.: Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J. Vet. Intern. Med. 1994, 8, 273-278.
• 35.Knapp D. W., Richardson R. C., DeNicola D. B., Long G. G., Blevins W. E.: Cisplatin toxicity in cats. J. Vet. Intern. Med. 1987, 1, 29-35.
• 36.Lenoir V., de Jonage-Canonico M. B., Perrin M. H., Martin A., Scholler R., Kerdelhué B.: Preventive and curative effect of melatonin on mammary carcinogenesis induced by dimethylbenz[a]anthracene in the female Sprague-Dawley rat. Breast Cancer Res. 2005, 7, R470-476.
• 37.Lerchl A., Schlatt S.: Influence of photoperiod on pineal melatonin synthesis, fur color, body weight, and reproductive function in the female Djungarian hamster, Phodopus sungorus. Neuroendocrinology 1993, 57, 359-564.
• 38.Lissoni P.: Is there a role for melatonin in supportive care? Support. Care Cancer. 2002, 10, 110-116.
• 39.Lissoni P., Barni S., Mandalà M., Ardizzoia A., Paolorossi F., Vaghi M., Longarini R., Malugani F., Tancini G.: Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumor patients with poor clinical status. Eur. J. Cancer. 1999, 35, 1688-1692.
• 40.Lissoni P., Barni S., Meregalli S., Fossati V., Cazzaniga M., Esposti D., Tancini G.: Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br. J. Cancer. 1995, 71, 854-856.
• 41.Lissoni P., Chilelli M., Villa S., Cerizza L., Tancini G.: Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J. Pineal. Res. 2003, 35, 12-15.
• 42.Lissoni P., Meregalli S., Fossati V., Paolorossi F., Barni S., Tancini G., Frigerio F.: A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer. Tumori. 1994, 80, 464-467.
• 43.MacEven E. G.: Spontaneous tumors In dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev. 1990, 9, 125-136.
• 44.Martin P. M., Cotard M., Maialot J. P., Andre F., Raynaud J. P.: Animal models for hormone-dependent human breast cancer. Relationship between steroid receptor profiles in canine and feline mammary tumors and survival rate. Cancer Chemother. and Pharmacology 1984, 12, 13-17.
• 45.Mediavilla M. D., Sanchez-Barcelo E. J., Tan D. X., Manchester L., Reiter R. J.: Basic mechanisms involved in the anti-cancer effects of melatonin. Curr. Med. Chem. 2010, 17, 4462-4481.
• 46.Owen L. N.: A comparative study of canine and human breast cancer. Invest. Cell Pathol. 1979, 2, 257-275.
• 47.Papavasiliou P. S., Cotzias G. C., Düby S. E., Steck A. J., Bell M., Lawrence W. H.: Melatonin and parkinsonism. JAMA 1972, 221, 88-89.
• 48.Pedro Eslava M., Giovanny Torres V.: Testicular neoplasms in dogs: A case of sertoli cell tumor (Neoplasias testiculares en caninos: Un caso de tumor de células de sertoli) Revista MVZ Cordoba 2008, 13, 1215-1225.
• 49.Rassnick K. M., Ruslander D. M., Cotter S. M., Al-Sarraf R., Bruyette D. S., Gamblin R. M., Meleo K. A., Moore A. S.: Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). J. Am. Vet. Med. Assoc. 2001, 218, 1444-1448.
• 50.Ravindra T., Lakshmi N. K., Ahuja Y. R.: Melatonin in pathogenesis and therapy of cancer. Indian J. Med. Sci. 2006, 60, 523-535.
• 51.Reiter R. J., Tan D. X., Sainz R. M., Mayo J. C., Lopez-Burillo S.: Melatonin: reducing the toxicity and increasing the efficacy of drugs. J. Pharm. Pharmacol. 2002, 54, 1299-1321.
• 52.Rouibah K., Houszka M.: Nowotwory żołądka u psów. Med. Weter. 2000, 56, 552-557.
• 53.Ruiz-Rabelo J. F., Vázquez R., Perea M. D., Cruz A., González R., Romero A., Muñoz-Villanueva M. C., Túnez I., Montilla P., Muntané J., Padillo F. J.: Beneficial properties of melatonin in an experimental model of pancreatic cancer J. Pineal Res. 2007, 43, 270-275.
• 54.Sánchez-Barceló E. J., Cos S., Fernández R., Mediavilla M. D.: Melatonin and mammary cancer: a short review. Endocr. Relat. Cancer. 2003, 10, 153-159.
• 55.Schernhammer E. S., Laden F., Speizer F. E., Willett W. C., Hunter D. J., Kawachi I., Colditz G. A.: Rotating night shifts and risk of breast cancer in women participating in the nurses’ health study. J. Natl. Cancer Inst. 2001, 93, 1563-1568.
• 56.Seabra M. L., Bignotto M., Pinto L. R. Jr., Tufik S.: Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J. Pineal Res. 2000, 29, 193-200.
• 57.Slominski A., Fischer T. W., Zmijewski M. A., Wortsman J., Semak I., Zbytek B., Slominski R. M., Tobin D. J.: On the role of melatonin in skin physiology and pathology. Endocrine. 2005, 27, 137-148.
• 58.Stevens R. G.: Electric power use and breast cancer: a hypothesis. Am. J. Epidemiol. 1987, 125, 556-561.
• 59.Tamarkin L., Danforth D., Lichter A., DeMoss E., Cohen M., Chabner B., Lippman M.: Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science 1982, 216,1003-1005.
• 60.Tan D. X., Reiter R. J., Manchester L. C., Yan M. T., El-Sawi M., Sainz R. M., Mayo J. C., Kohen R., Allegra M., Hardeland R.: Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr. Top. Med. Chem. 2002, 2, 181-197.
• 61.Viswanathan A. N., Schernhammer E. S.: Circulating melatonin and the risk of breast and endometrial cancer in women. Cancer Lett. 2009, 281, 1-7.
• 62.Wenger M., Hauser B., Ohlerth S., Hassig M., Fidel J. L., Reusch C. E.: Thyroid neoplasms in dogs: a retrospective study of 17 cases eine retrospektive Studie uber 17 Falle. Kleintierpraxis 2005, 50, 479-488.
• 63.Zań R., Roliński Z., Kowalski C., Burmańczuk A., Polska B.: Melatonina, jej właściwości biologiczne i możliwe zastosowania kliniczne u ludzi oraz zwierząt. Życie wet. 2011, 86, 225-228.
• 64.Zań R., Roliński Z., Kowalski C., Duda M.: Czy melatonina jest niezbędna również dla zwierząt? Magazyn wet. 2011, 20, 251-253.